Catharina Wilhelmina Menke

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.

Marina Maglakelidze, Iurie Bulat, Dinara Ryspayeva et al. · Journal of Clinical Oncology · 2021 · 26 citations

Medicine, Oncology, Pharmacology +17

PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).

Géraldine Gebhart, Laetitia E. Lamberts, Camilo Garcia et al. · Journal of Clinical Oncology · 2014 · 18 citations

Medicine, Nuclear Medicine, Immunotherapy +14

A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.

Florence Atrafi, Herlinde Dumez, Ron H.J. Mathijssen et al. · Journal of Clinical Oncology · 2019 · 17 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.

Jan H.M. Schellens, Josep Tabernero, Ulrik Lassen et al. · Journal of Clinical Oncology · 2015 · 14 citations

Medicine, Immunology, Oncology +17

EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.

Éric Baudin, Camilo Jiménez, Salvatore Grisanti et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Immunology, Oncology +17